Shohei Yamamoto Makoto Otsu Emiko Matsuzaka Chieko Konishi Haruna Takagi Sachiyo Hanada Shinji Mochizuki Hiromitsu Nakauchi Kohzoh Imai Kohichiro Tsuji Yasuhiro Ebihara
10.1371/journal.pone.0120841
PLoS One
2015 Mar 24;10(3):e0120841.
CC BY
https://pubmed.ncbi.nlm.nih.gov/25803811/
Induced Pluripotent Stem Cells / drug effects Myeloproliferative Disorders / drug therapy Myeloproliferative Disorders / genetics Oncogene Proteins, Fusion / genetics Protein Kinase Inhibitors / therapeutic use Receptor, Fibroblast Growth Factor, Type 1 / genetics Translocation, Genetic
Induced Pluripotent Stem Cells / drug effects Myeloproliferative Disorders / drug therapy Myeloproliferative Disorders / genetics Oncogene Proteins, Fusion / genetics Protein Kinase Inhibitors / therapeutic use Receptor, Fibroblast Growth Factor, Type 1 / genetics Translocation, Genetic Case Reports Research Support, Non-U.S. Gov't Adolescent Benzimidazoles / therapeutic use Cells, Cultured Drug Evaluation, Preclinical Hematopoiesis Humans Imatinib Mesylate / therapeutic use Imidazoles / therapeutic use Induced Pluripotent Stem Cells / metabolism Induced Pluripotent Stem Cells / pathology Male Myeloproliferative Disorders / pathology Pyridazines / therapeutic use Quinolones / therapeutic use Staurosporine / analogs & derivatives Staurosporine / therapeutic use 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one Benzimidazoles Imidazoles Oncogene Proteins, Fusion Protein Kinase Inhibitors Pyridazines Quinolones ponatinib Imatinib Mesylate Receptor, Fibroblast Growth Factor, Type 1 CEP110-FGFR1 fusion protein, human Staurosporine midostaurin
PMC4372437
25803811
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1
2015